Introduction {#s1}
============

Growth factors and their cognate receptor tyrosine kinases (RTK) are key regulators of tumor cell initiation and progression [@pone.0013587-Mosesson1]. Growth factor binding and subsequent RTK auto-phosphorylation lead to the activation of pathways that regulate cell proliferation, survival, growth, adhesion and motility. Inappropriate RTK activation can drive tumor cell growth, survival, invasion and metastasis. RTKs like epidermal growth factor receptor (EGFR) and epidermal growth factor receptor 2 (Her2/ERBB2) are overexpressed or activated in a variety of human cancers [@pone.0013587-Yarden1]. In non-small cell lung cancers (NSCLC), activating *EGFR* mutations are found in 10--15% of Caucasian and 30--40% Asian patients [@pone.0013587-Hynes1], [@pone.0013587-Engelman1]. ERBB2, as a further example, is upregulated by gene amplification in 15--30% of invasive mammary ductal cancers [@pone.0013587-Mosesson1]. RTKs are known to activate several downstream tyrosine kinases, including members of the SRC, ABL, and JAK kinase families. These cytosolic kinases make a significant contribution to the dramatic increase in tyrosine phosphorylation induced by RTKs. It has been difficult to define the precise subset of proteins targeted by any individual tyrosine kinase that is a component of these kinase signaling cascades due to the overlap in substrates phosphorylated by activated RTKs and non-receptor tyrosine kinases. Previous studies have utilized activated mutant variants of non-receptor tyrosine kinases like SRC to identify downstream substrates of this kinase subfamily; however, these overexpressed, constitutively active mutants likely display promiscuous activities that do not necessarily reflect the substrates of the endogenous protein when activated by an upstream RTK.

SRC and other SRC family kinases (SFKs) are activated downstream of many different RTKs [@pone.0013587-Thomas1]. SRC activity is critical for several phenotypic events induced by RTK activation including DNA synthesis, cytoskeletal reorganization and disruption of cell-cell adhesion [@pone.0013587-Courtneidge1], [@pone.0013587-Alvarez1], [@pone.0013587-Wrobel1]. In human tumors, RTK activation of SFKs may contribute to tumor progression and lead to more aggressive tumor phenotypes [@pone.0013587-Yeatman1]. Dominant negative SRC mutants, pharmacological inhibition of SRC kinase activity, and SRC-specific docking site RTK mutants have been used to address the specific role of SRC in RTK signal transduction [@pone.0013587-Bromann1]. Studies in breast cancer models using these methods have demonstrated that inhibition of SRC kinase activity suppresses phenotypic effects induced by the overexpression or activation of RTKs like EGFR and ERBB2, e.g. anchorage-independent growth, motility and survival [@pone.0013587-Bromann1], [@pone.0013587-Summy1], [@pone.0013587-Ishizawar1], [@pone.0013587-Finn1]. Therefore, RTK-induced SRC activity drives aspects of RTK signaling important in tumor progression, and the identification of RTK-induced SRC substrates will offer further insight into the role of SRC in tumorigenesis.

We previously demonstrated [@pone.0013587-Wrobel1] that Src activation regulates a subset of phenotypic alterations induced by the colony stimulating factor 1 receptor tyrosine kinase (CSF-1R), which has been implicated in the progression of multiple types of carcinoma including breast cancer [@pone.0013587-Patsialou1], [@pone.0013587-Flick1], [@pone.0013587-Maher1], [@pone.0013587-Sapi1], [@pone.0013587-Chambers1], [@pone.0013587-Kacinski1], [@pone.0013587-Toy1]. SRC activity was found to be critical for CSF-1R-induced disruption of cell-cell adhesion of MCF-10A cells, immortalized, non-transformed mammary epithelial cells [@pone.0013587-Wrobel1]. These alterations are associated with loss of plasma membrane association of E-cadherin, a key regulator of epithelial intercellular adhesion. The CSF-1R tyrosine phosphorylation site that binds to SRC and other SFKs, Y561, was found to be critical for disruption of cell-cell adhesion [@pone.0013587-Wrobel1], [@pone.0013587-Alonso1]. Expression of a dominant-negative mutant of SRC (c-SRC K295R) or pharmacological inhibition of SRC kinase activity in the presence of CSF-1R activation preserves cell-cell adhesion, providing additional evidence that SRC activity and phosphorylation of SRC substrates are involved in the disruption observed [@pone.0013587-Wrobel1].

Few studies have examined the specific set of SRC substrates phosphorylated after RTK activation [@pone.0013587-Bromann1], [@pone.0013587-Amanchy1]. A recent mass spectrometry (MS) analysis by Amanchy and colleagues identified 43 candidate SRC substrates downstream of platelet-derived growth factor (PDGF) receptor in fibroblasts using SU6656, a pharmacological inhibitor of SRC kinase activity [@pone.0013587-Amanchy1]. While this work identified candidate substrates of endogenous SRC, all cellular SRC family kinases were inhibited by this inhibitor, so this analysis did not distinguish substrates that are directly downstream of PDGFR activation from those regulated by adhesion receptors and other cellular processes. Several MS analyses have identified proteins that display increased tyrosine phosphorylation in cells overexpressing wild-type SRC or an activated mutant variant [@pone.0013587-Rush1], [@pone.0013587-Leroy1], [@pone.0013587-Luo1], [@pone.0013587-Amanchy2]. However, the relevance of these targets in human tumors is not clear, as SRC is not frequently mutated or overexpressed in breast cancers, and it is more likely activated in breast carcinomas by an upstream activated RTK or another receptor known to couple to SRC [@pone.0013587-Thomas1], [@pone.0013587-Bromann1], [@pone.0013587-Summy1], [@pone.0013587-Finn1], [@pone.0013587-Russello1].

Using quantitative MS analysis, we examined CSF-1R-induced tyrosine phosphorylation using quantitative PhosphoScan® analysis. PhosphoScan® analysis is an MS approach that utilizes immunoaffinity purification of tyrosine phosphorylated peptides prior to MS analysis to enrich their representation in the sample [@pone.0013587-Rush1]. We profiled site-specific changes in tyrosine phosphorylation induced by activated CSF-1R and activated CSF-1R defective for the recruitment of SFKs in MCF-10A cells. To do this, we utilized a previously described constitutively active variant of CSF-1R (CA-CSF-1R) and CA-CSF-1R with a tyrosine to phenylalanine substitution at Y561 (CA-CSF-1R Y561F), the recruitment site for SRC and SFKs [@pone.0013587-Wrobel1]. This phosphotyrosine proteomic MS analysis of parental MCF-10As and cells expressing the two CSF-1R variants allowed us to characterize CSF-1R-induced tyrosine phosphorylation events and to distinguish Y561-independent and Y561-dependent phosphorylation events stimulated by the activated CSF-1R. The Y561-dependent substrates revealed a set of putative SRC substrates and subsequent bioinformatics analyses of these targets in human tumor datasets identified potential biomarkers of SRC activation in human tumors.

Results {#s2}
=======

Quantitative MS analysis {#s2a}
------------------------

To systematically profile changes in tyrosine phosphorylation downstream of CSF-1R activation and identify candidate SRC substrates, we conducted quantitative liquid chromatography and tandem MS (LC-MS/MS) analysis using metabolic labeling with stable isotopes (SILAC) together with phosphotyrosine proteome analysis using samples derived from MCF-10A cells expressing either CA-CSF-1R or CA-CSF-1R Y561F [@pone.0013587-Rush1]. For quantitative analysis using SILAC, one experimental sample is labeled with "heavy" amino acids, while the other sample is grown in the presence of "light" amino acids. In this study, CA-CSF-1R-expressing MCF-10A cells were labeled with "heavy" ^13^C~6~-^15^N~2~-L-lysine and ^13^C~6~-^15^N~4~-L-arginine. Cells expressing CA-CSF-1R Y561F and parental MCF-10A cells were labeled with the corresponding "light" isotopic variants of the same amino acids ([Figure 1A](#pone-0013587-g001){ref-type="fig"}). Naturally occurring amino acid isotopic variants were eliminated from the serum supplementing the growth medium by dialysis, and cells were passaged a minimum of five times in the labeling medium to ensure complete incorporation of the labeled amino acid. Before harvesting for phosphotyrosine proteome analysis, the cells were cultured in the absence of EGF, as EGF-starvation leads to dominant CSF-1R signaling in MCF-10A cells overexpressing the CSF-1R [@pone.0013587-Wrobel1]. Samples were mixed in a 1∶1 "heavy/light" ratio, proteolytically digested, and subjected to phosphotyrosine immunoprecipitation prior to LC-MS/MS.

![Quantitative MS profiles CSF-1R-induced and SRC-dependent changes in tyrosine phosphorylation in MCF-10A cells.\
**A**) Schematic of experimental design showing the CSF-1R constitutively active mutants used in MCF-10A cells to profile changes in tyrosine phosphorylation and the protocol followed for quantitative MS analysis **B**) Graph of data from quantitative MS analysis depicting the distribution of peptides relative to the fold change in tyrosine phosphorylation levels. Blue: CA-CSF-1R vs. parental MCF-10A; Red: CA-CSF-1R vs. CA-CSF-1R Y561F MCF-10A.](pone.0013587.g001){#pone-0013587-g001}

We quantitatively assessed the tyrosine phosphorylation of 275 peptides in the comparison of CA-CSF-1R MCF-10A cells to parental MCF-10A cells ([Table S1](#pone.0013587.s001){ref-type="supplementary-material"}), and 324 peptides in the comparison of CA-CSF-1R MCF-10A cells to CA-CSF-1R Y561F MCF-10A cells ([Table S2](#pone.0013587.s002){ref-type="supplementary-material"}). The fold differences in tyrosine phosphorylated peptides were calculated by determining the ratio of tyrosine phosphorylated peptides detected in each of the cell pairs e.g., CA-CSF-1R vs. parental MCF-10A cells or CA-CSF-1R vs. CA-CSF-1R Y561F cells ([Figure 1A](#pone-0013587-g001){ref-type="fig"}). [Figure 1B](#pone-0013587-g001){ref-type="fig"} illustrates the distribution of the identified phosphopeptides for each comparison (CA-CSF-1R/MCF-10A; CA-CSF-1R/CA-CSF-1R Y561F) relative to the fold change differences in tyrosine phosphorylation.

CSF-1R induced changes in phosphorylation {#s2b}
-----------------------------------------

To guide our assignment of the threshold for significant fold changes phosphorylation, we first graphed the distribution of the non-phosphorylated peptides present in the immunoprecipitated samples and determined the mean of the quantitative fold change values. We assumed data normality based on these distributions; therefore, fold change values greater than two deviations from the mean are considered 95% likely to represent significant differences in tyrosine phosphorylation. Each comparison had a different mean value for the non-phosphopeptide distribution; however, the same statistical threshold was applied to both comparisons. For the CA-CSF-1R/parental MCF-10A comparison, fold change ratios \>1.94 were defined as an upregulation in the levels of tyrosine phosphorylation, ratios 0.64--1.94 as unchanged, and ratios \<0.64 as a downregulation of tyrosine phosphorylation.

100 tyrosine sites on 74 proteins were phosphorylated above threshold level in cells expressing CA-CSF-1R relative to parental MCF-10A cells and were defined as "CSF-1R-induced" ([Table 1](#pone-0013587-t001){ref-type="table"}). The threshold value (ratio \>1.94) used in this analysis was based on a statistical analysis comparing non-phosphorylated and phosphorylated peptides detected in the screen (see [Materials and Methods](#s4){ref-type="sec"}). Five tyrosine sites on four proteins exhibited lower tyrosine phosphorylation in CA-CSF-1R cells and were classified as "CSF-1R downregulated". Forty-five tyrosine residues on 36 proteins exhibited no change in the level of tyrosine phosphorylation upon CSF-1R activation and were labeled as "basally phosphorylated" and are likely substrates of kinases basally active in MCF-10A cells ([Table S3](#pone.0013587.s003){ref-type="supplementary-material"}).

10.1371/journal.pone.0013587.t001

###### Peptides with CSF-1R induced tyrosine phosphorylation in MCF-10A cells.

![](pone.0013587.t001){#pone-0013587-t001-1}

  Protein Name            UniProt\#   NCBI Site    Fold change[\*](#nt101){ref-type="table-fn"} (CA-CSF-1R/MCF-10A)   Fold change[\*](#nt101){ref-type="table-fn"} (CA-CSF-1R/Y561F)   Src regulation
  ---------------------- ----------- ------------ ------------------------------------------------------------------ ---------------------------------------------------------------- -----------------
  Transferrin receptor     P02786        Y20                                    313.67                                                              \-                                
  APLP2                    Q06481        Y750                                   73.37                                                               \-                                
  D-Prohibitin             Q99623        Y248                                  \>55.42                                                              \-                                
  PAR3                     Q8TEW0        Y489                                  \>34.42                                                              \-                                
  PKM2                    P14618-2       Y105                                   29.01                                                               \-                                
  PIK3R1                   P27986        Y470                                  \>24.59                                                              \-                                
  PIK3R1                   P27986        Y607                                  \>22.45                                                              \-                                
  PAR3                     Q8TEW0        Y719                                   19.88                                                               \-                                
  LAPTM4A                  Q15012        Y230                                  \>18.02                                                              \-                                
  TAOK1                    Q7L7X3        Y309                                  \>17.57                                                              \-                                
  PIK3R2                   O00459        Y577                                  \>13.95                                                              \-                                
  Beta-adaptin             P63010        Y277                                  \>12.57                                                              \-                                
  UBXD8                    Q96CS3        Y79                                   \>12.42                                                              \-                                
  UQCRC2                   P22695        Y207                                  \>10.13                                                              \-                                
  HSP90-beta               P08238        Y483                                    9.54                                                               \-                                
  CCT-theta                P50990        Y29                                     9.4                                                                \-                                
  Syndecan-4               P31431        Y197                                    6.8                                                                \-                                
  CSF-1R                   P07333        Y556                                   \>5.68                                                              \-                                
  CDC2                     P06493        T14                                     4.18                                                               \-                                
  EphA2                    P29317        T593                                 3.58;3.58                                                             \-                                
  CDC2                     P06493        Y19                                     3.36                                                               \-                                
  IRS2                     Q9Y4H2        Y598                                    3.27                                                               \-                                
  CASKIN-2                 Q8WXE0        Y253                                    3.21                                                               \-                                
  Desmoglein               Q14126       Y1013                                    2.06                                                               \-                                
  EphB4                    P54760        Y774                               2.03;2.03;2.03                                                      1.75;1.75                               Src-dependent
  FLJ20625                 Q9NWT0        Y40                                   \>19.60                                                             2.06                                 Src-dependent
  EphA2                    P29317        Y575                                    3.28                                                              2.11                                 Src-dependent
  Beta-adaptin             P63010        Y276                               \>11.05;26.66                                                          2.12                                 Src-dependent
  KIAA0323                 O15037        Y456                           \>14.07;150.39;105.93                                               2.22;1.98;1.98;1.7                          Src-dependent
  Intersectin 2            Q9NZM3        Y552                                   51.99                                                           2.73;2.73                               Src-dependent
  ACK                      Q07912        Y518                                    2.29                                                              3.45                                 Src-dependent
  Hrs                      O14964        Y216                                   148.61                                                           3.51;3.5                               Src-dependent
  ZDHHC7                   Q9NXF8        Y130                               \>50.78;173.17                                                    4.05;3.99;3.98                            Src-dependent
  TJAP1                    Q5JTD0        Y352                                  \>88.49                                                             4.31                                 Src-dependent
  Hrs                      O14964        Y334                               \>34.54;229.48                                                         4.49                                 Src-dependent
  Hrs                      O14964        Y132                        \>296.57;1823.09;28.34;8.78                                    5.06;3.12;3.12;3.11;3.11;2.63;2.63                  Src-dependent
  p120 catenin             O60716        Y904                                 3.27;3.27                                                         5.31;5.31                               Src-dependent
  CSF-1R                   P07333        Y561                                  \>37.45                                                           \>16.44                                Src-dependent
  STAT3                   P40763-2       Y704                               4.85;4.45;4.45                                                    0.73;0.72;0.72                           Src-independent
  Plakophilin 3            Q9Y446        Y176                                 2.37;2.37                                                            0.74                                Src-independent
  RPS10                    P46783        Y12                                    10.35                                                           0.74;0.74                              Src-independent
  STAT3                    P40763        Y705                            4.76;4.76;4.64;4.64                                                    0.77;0.77                              Src-independent
  Insulin Receptor         P06213       Y1189                                    2.41                                                         0.84;0.84;0.73                           Src-independent
  Talin 1                  Q9Y490        Y70                                    31.66                                                              0.84                                Src-independent
  ACLY                     P53396       Y1073                              \>26.05;\>11.93                                                       0.9;0.9                               Src-independent
  SHB                      Q15464        Y246                                    2.78                                                              0.93                                Src-independent
  LDLR                     P01130        Y845                                61.43;32.64                                                           1;1                                 Src-independent
  CSF-1R                   P07333        Y809                        \>45.71;\>20.07;1292.56;10.6                                               1.01;1.01                              Src-independent
  EphA2                    P29317        Y588                                    4.61                                                              1.07                                Src-independent
  SHB                      Q15464        Y268                                 2.91;2.91                                                         1.09;1.09                              Src-independent
  Calmodulin               P62158        Y99                                 127.33;70.6                                                   1.11;1.11;0.93;0.93                         Src-independent
  PTTG1IP                  P53801        Y174                               \>30.11;17.83                                                     1.15;1.11;1.11                           Src-independent
  EphA2                    P29317        Y772                               3.79;3.32;3.32                                                 1.16;1.16;1.09;1.09                         Src-independent
  Integrin beta-4          P16144       Y1207                            2.33;2.33;1.39;1.39                                                       1.18                                Src-independent
  GSTP1                    P09211         Y7                                    35.59                                                           1.19;1.19                              Src-independent
  eEF1A-2                  Q05639        Y29                                     3.45                                                           0.65;0.65                              Src-independent
  PKC, Delta               Q05655        Y374                                   \>9.84                                                             0.65                                Src-independent
  RPS27                    P42677        Y31                                     7.36                                                           0.66;0.66                              Src-independent
  CDC2                     P06493      T14, Y15                               5.41;5.27                                                         0.67;0.58                              Src-independent
  Vimentin                 P08670        Y53                                     2.15                                                              0.68                                Src-independent
  PIK3R1                   P27986        Y467                                    6.15                                                         0.68;0.64;0.64                           Src-independent
  Annexin A2               P07355        Y29                               12.46;5.27;5.27                                                      0.69;0.69                              Src-independent
  KIAA1217                 Q5T5P2        Y244                                 3.08;3.07                                                          0.7;0.7                               Src-independent
  PIN4                     Q9Y237        Y122                                  \>21.65                                                        0.75;0.68;0.68                           Src-independent
  CSF-1R                   P07333        Y699                       \>8.52;\>38.88;\>32.34;\>13.82                          0.76;0.74;0.73;0.68;0.66;0.66;0.66;0.62;0.56;0.56          Src-independent
  CSF-1R                   P07333        Y923                                  \>133.30                                                          0.8;0.63                              Src-independent
  Ack                      Q07912        Y857                                    4.37                                                        1.13; 1.01; 1.01                          Src-independent
  EphA2                    P29317     Y588, Y594                              4.53;3.66                                                      1.16; 0.62; 0.62                          Src-independent
  CSF-1R                   P07333        Y873                              \>56.43;\>38.15                                                    1.3; 1.3; 1.21                           Src-independent
  Caveolin 1               Q03135        Y14                                3.53;2.92;2.74                                                    0.67;0.57;0.53                            Src-inhibited
  SLC20A1                  Q8WUM9        Y388                                  \>13.04                                                             0.25                                 Src-inhibited
  HGK                      O95819       Y1227                                  \>15.71                                                          0.28;0.28                               Src-inhibited
  GAB1                     Q13480        Y659                                   16.82                                                              0.31                                 Src-inhibited
  ERK2                     P28482     T184, Y186                                56.77                                                           0.31;0.31                               Src-inhibited
  PTRF                     Q6NZI2        Y308                            6.84;6.13;0.96;0.94                                             0.35;0.35;0.34;0.28;0.28                       Src-inhibited
  Annexin A1               P04083        Y38                                    19.83                                                           0.42;0.42                               Src-inhibited
  H2B2E                    Q16778        Y43                               \>31.63;1152.72                                                    0.43;0.42;0.42                            Src-inhibited
  Plakophilin 3            Q9Y446        Y84                                 67.23;57.48                                                   0.43;0.43;0.42;0.42                          Src-inhibited
  ARP2/3 Subunit 3         O15145        Y46                                    \>9.76                                                             0.44                                 Src-inhibited
  PDLIM5                   Q96HC4        Y251                                    5.23                                                              0.49                                 Src-inhibited
  UrdPase 1                Q16831        Y35                                    16.85                                                              0.49                                 Src-inhibited
  p120 catenin             O60716        Y96                                     2.33                                                              0.5                                  Src-inhibited
  SHC1                     P29353        Y427                            5.87;5.87;5.53;5.53                                                       0.51                                 Src-inhibited
  FAM62A                   Q9BSJ8        Y822                                    7.99                                                              0.51                                 Src-inhibited
  ERK1                     P27361        Y204                                   27.99                                                              0.52                                 Src-inhibited
  Annexin A2               P07355        Y315                                   236.05                                                          0.52;0.52                               Src-inhibited
  CDK3                     Q00526        Y15                                7.46;4.62;4.61                                               0.53;0.53;0.43;0.21;0.21                       Src-inhibited
  Annexin A2               P07355        Y237                             11.78;11.75;10.71                                                   0.53;0.53;0.47                            Src-inhibited
  ERK2                     P28482        Y186                                35.57;18.11                                                      0.53;0.53;0.47                            Src-inhibited
  Enolase 1                P06733        Y188                                    2.46                                                              0.54                                 Src-inhibited
  Annexin A2               P07355        Y23                                 3.3;3.3;2.96                                             0.56;0.56;0.56;0.56;0.55;0.55                     Src-inhibited
  SLC38A2                  Q9HAV3        Y41                                     21.5                                                           0.56;0.56                               Src-inhibited
  PIK3R1                   P27986        Y580                          \>56.64;79.89;36.8;36.73                             0.57;0.57;0.57;0.56;0.56; 0.54;0.54;0.52;0.51;0.51          Src-inhibited
  DLG1                     Q12959        Y760                                  \>11.65                                                          0.59;0.51                               Src-inhibited
  DLG3                     Q92796        Y673                               \>12.59;128.61                                                      0.59;0.59                               Src-inhibited
  VASP                     P50552        Y38                                    109.16                                                             0.59                                 Src-inhibited
  LDH-A                    P00338        Y238                                   18.81                                                            0.6;0.6                                Src-inhibited
  Vimentin                 P08670        Y61                                     2.01                                                              0.61                                 Src-inhibited
  PZR                      O95297        Y263                           12.21;10.01;7.27;7.27                                               0.62;0.62;0.6;0.6                           Src-inhibited
  NHP2L1                   P55769        Y31                                   \>16.86                                                             0.62                                 Src-inhibited
  Cdc2                     P06493        Y15                                4.69;4.69;4.18                                          0.79;0.61;0.55;0.55;0.55;0.49;0.49                  Src-inhibited
  H2B1L                    Q99880        Y42                                   \>113.37                                                    0.53;0.53;0.42;0.42                          Src-inhibited
  CNP                      P09543        Y110                                    2.8                                                         0.48; 0.48; 0.44                           Src-inhibited
  CDK3                     Q00526        Y19                                 870.42;4.62                                                        0.52; 0.52                              Src-inhibited

\*Multiple peptides were detected for tyrosine sites with multiple values.

An additional 38 tyrosine sites on 36 proteins were found to be phosphorylated in the CA-CSF-1R vs. CA-CSF-1R Y561F analysis, but not detected in the CA-CSF-1R vs. parental MCF-10A analysis. These sites were denoted "CSF-1R induced\*" ([Table 2](#pone-0013587-t002){ref-type="table"}). It remains a possibility that these sites are not CSF-1R induced, but were undetectable in the parental MCF-10As from the CA-CSF-1R vs. MCF-10A MS analysis. However, these sites were denoted as CSF-1R-induced\* to distinguish them as qualified CSF-1R regulated sites ([Table 2](#pone-0013587-t002){ref-type="table"}). Where these phosphorylated tyrosine residues are included in later comparative analyses they are clearly distinguished. Inclusion of these sites adds 24 CSF-1R induced\* proteins (twelve proteins had other tyrosine sites that were unambiguously CSF-1R induced). Further validation will be necessary to determine whether this subset of proteins is regulated by CSF-1R activation. Overall, we identified 98 proteins with either CSF-1R-induced (74 proteins) or CSF-1R induced\* (24 proteins) tyrosine phosphorylation.

10.1371/journal.pone.0013587.t002

###### Proteins with CSF-1R induced\* tyrosine phosphorylation detected in CA-CSF-1R v CA-CSF-1R Y561F analysis.

![](pone.0013587.t002){#pone-0013587-t002-2}

  Protein Name            UniProt\#    NCBI Site     Fold change   Src regulation
  ---------------------- ----------- -------------- ------------- -----------------
  STAT 5A                  P42229         Y694        2.11;2.11     Src-dependent
  EphB4                    P54760      T587, Y595       2.09        Src-dependent
  RAN                      P62826         Y146          1.81        Src-dependent
  SPG20                    Q8N0X7         Y46           1.66        Src-dependent
  RPS13                    P62277         Y37           1.49       Src-independent
  PIK3R3                   Q92569         Y373          1.43       Src-independent
  HGF-R                    P08581        Y1234        1.21;1.21    Src-independent
  Cofilin                  P23528         Y139        1.14;0.79    Src-independent
  p38-alpha               Q16539-2        Y182        1.03;1.03    Src-independent
  Insulin Receptor         P06213     Y1185, Y1189    0.77;0.77    Src-independent
  EphA2                    P29317         Y594        0.74;0.74    Src-independent
  Transferrin receptor     P02786         S19           1.28       Src-independent
  LDH-B                    P07195         Y239          1.23       Src-independent
  KIRREL                   Q96J84         Y724          1.17       Src-independent
  FLJ20625                 Q9NWT0         Y140          1.13       Src-independent
  GUK1                     Q16774         Y52           1.03       Src-independent
  Yes                      P07947         Y221          0.99       Src-independent
  D-Prohibitin             Q99623         Y121          0.95       Src-independent
  MGC14839                 Q96A22         Y78           0.92       Src-independent
  ADK2                     P54819         Y200          0.86       Src-independent
  ADK2                     P54819         Y199          0.86       Src-independent
  KIRREL                   Q96J84         Y605          0.85       Src-independent
  Crk                      P46108         Y221          0.77       Src-independent
  Caveolin 1               Q03135         Y25           0.69       Src-independent
  Pyk2                     Q14289      Y579, Y580       0.67       Src-independent
  STEAP1                   Q9UHE8         Y27           0.66       Src-independent
  KRT81                    Q14533         Y282          0.64       Src-independent
  CDK3                     Q00526       T14, Y15      0.61;0.61     Src-inhibited
  NDUFB10                  O96000         Y54           0.62        Src-inhibited
  SHC1                     P29353         Y350          0.62        Src-inhibited
  PGK1                     P00558         Y196          0.61        Src-inhibited
  EGF-R                    P00533        Y1197           0.6        Src-inhibited
  ZDHHC5                   Q9C0B5      S529 Y533        0.53        Src-inhibited
  PI3K p110 alpha          P42336         Y508          0.45        Src-inhibited
  GAB1                     Q13480         Y406          0.27        Src-inhibited
  MGC32065                 Q8WV41         Y264          0.22        Src-inhibited
  H2B1L                    Q99880         Y40           0.43        Src-inhibited
  PTRF                     Q6NZI2         Y156        0.45;0.45     Src-inhibited

As expected, CSF-1R activation in parental MCF-10A cells induced a strong increase in tyrosine phosphorylation. Proteins previously shown to be tyrosine phosphorylated following CSF-1R activation were detected in our analysis ([Table 3](#pone-0013587-t003){ref-type="table"}), thus validating this approach for identification of CSF-1R substrates. These included STAT3, PKCδ, vimentin, SHC1, annexin A1, multiple isoforms of PI3K p85-alpha, ERK1, ERK2, and tyrosine residues on the CSF-1R (Y556, Y561, Y699, Y809, Y873, Y923) [@pone.0013587-Pixley1], [@pone.0013587-Yeung1], [@pone.0013587-Douglass1]. Similarly, the CSF-1R-induced\* set of proteins included STAT5A, YES, PYK2 and p38-alpha, which are known to be phosphorylated downstream of CSF-1R ([Table 1](#pone-0013587-t001){ref-type="table"}).

10.1371/journal.pone.0013587.t003

###### Profile of known CSF-1R induced changes in tyrosine phosphorylation in MCF-10A cells.

![](pone.0013587.t003){#pone-0013587-t003-3}

  Protein Name    UniProt \#   NCBI Site    Fold change (CA-CSF-1R/MCF10A)              Function
  -------------- ------------ ------------ -------------------------------- --------------------------------
  Annexin A1        P04083        Y38                   19.83                   Calcium-binding protein
  CSF-1R            P07333        Y923                 \>133.30              Receptor tyrosine kinase (RTK)
  CSF-1R            P07333        Y873                 \>56.43                            RTK
  CSF-1R            P07333        Y809                 \>45.71                            RTK
  CSF-1R            P07333        Y699                 \>38.88                            RTK
  CSF-1R            P07333        Y873                 \>38.15                            RTK
  CSF-1R            P07333        Y561                 \>37.45                            RTK
  CSF-1R            P07333        Y699                 \>32.34                            RTK
  CSF-1R            P07333        Y809                 \>20.07                            RTK
  CSF-1R            P07333        Y699                 \>13.82                            RTK
  CSF-1R            P07333        Y699                  \>8.52                            RTK
  CSF-1R            P07333        Y556                  \>5.68                            RTK
  CSF-1R            P07333        Y809                 1292.56                            RTK
  ERK 1             P27361        Y204                  27.99                   Protein kinase, Ser/Thr
  ERK 2             P28482     T184, Y186               56.77                   Protein kinase, Ser/Thr
  PIK3R1            P27986        Y580                 \>56.64                       Kinase, lipid
  PIK3R1            P27986        Y470                 \>24.59                       Kinase, lipid
  PIK3R1            P27986        Y607                 \>22.45                       Kinase, lipid
  PIK3R1            P27986        Y580                  79.89                        Kinase, lipid
  PIK3R1            P27986        Y580                   36.8                        Kinase, lipid
  PIK3R1            P27986        Y580                  36.73                        Kinase, lipid
  PIK3R1            P27986        Y467                   6.15                        Kinase, lipid
  PIK3R2            O00459        Y577                 \>13.95                       Kinase, lipid
  PKC delta         Q05655        Y374                  \>9.84                  Protein kinase, Ser/Thr
  SHC1              P29353        Y427                   5.87                       Adaptor/scaffold
  SHC1              P29353        Y427                   5.87                       Adaptor/scaffold
  SHC1              P29353        Y427                   5.53                       Adaptor/scaffold
  SHC1              P29353        Y427                   5.53                       Adaptor/scaffold
  STAT3             P40763        Y705                   4.76                     Transcription factor
  STAT3             P40763        Y705                   4.76                     Transcription factor
  STAT3             P40763        Y705                   4.64                     Transcription factor
  STAT3             P40763        Y705                   4.64                     Transcription factor
  Vimentin          P08670        Y61                    2.01                     Cytoskeletal protein
  Vimentin          P08670        Y53                    2.15                     Cytoskeletal protein

GeneGO® enrichment analysis of the CSF-1R-induced and CSF-1R-induced\* protein set revealed that CSF-1R induces phosphorylation of proteins associated with cellular processes including cell adhesion, developmental pathways, translation initiation, cell cycle regulation, and cytoskeletal dynamics ([Figure 2A](#pone-0013587-g002){ref-type="fig"}). Interestingly, CSF-1R activation stimulates phosphorylation of proteins involved in immune and inflammation pathways e.g., interleukin (IL)-6 and IL-2 signaling and neutrophil activation. Phosphorylation of these targets in MCF-10A cells may reflect the conserved function of CSF-1R in the regulation of monocyte cell differentiation and survival. Proteins with CSF-1R-induced tyrosine phosphorylation that contribute to the enriched biological processes are listed in [Table S4](#pone.0013587.s004){ref-type="supplementary-material"}. We also analyzed the CSF-1R-induced and CSF-1R-induced\* proteins for significant association with disease and found a statistically significant enrichment for proteins involved in tumor metastasis and progression ([Figure 2A](#pone-0013587-g002){ref-type="fig"}, [Table S4](#pone.0013587.s004){ref-type="supplementary-material"}).

![CSF-1R-induced changes in tyrosine phosphorylation.\
**A**) GeneGO® enrichment analysis of proteins with CSF-1R-induced and CSF-1R-induced\* tyrosine phosphorylation. The 20 most significant GeneGO® Processes (black) and 5 most significant diseases (blue) are shown. Enrichment scores are −log(p-value). **B**) Diagram depicting the overlap in phosphorylated proteins between the CSF-1R, EGFR and ERBB2 pathways. Thirty-five proteins were unique to CSF-1R (blue), nineteen were in one other pathway (light gray), fourteen were in two (dark gray), and three were common to all studies (green). The EGFR/CSF-1R overlapping proteins are listed in [Table S5](#pone.0013587.s005){ref-type="supplementary-material"}.](pone.0013587.g002){#pone-0013587-g002}

Comparative phosphoproteomics -- EGFR and ERBB2-induced tyrosine phosphorylation {#s2c}
--------------------------------------------------------------------------------

MCF-10A cells over-expressing CA-CSF-1R are able to proliferate and survive in the absence of EGF, suggesting that CSF-1R and EGFR activate redundant signaling pathways to some degree [@pone.0013587-Wrobel1]. The quantitative MS data show that under EGF-deficient experimental conditions phosphorylation of EGFR on Y1172 was equivalent in parental MCF-10As and CA-CSF-1R MCF-10As ([Table S1](#pone.0013587.s001){ref-type="supplementary-material"}). This data indicates that CSF-1R activation does not influence EGFR directly, but independently activates downstream pathways that promote proliferation and survival.

To identify phosphorylated targets common to CSF-1R and other growth factor receptors, we compared our dataset with other available phosphoproteomic datasets. Heibeck and colleagues utilized phosphotyrosine peptide immunoprecipitation and high sensitivity capillary LC-MS/MS to identify 481 basal and EGF-induced tyrosine phosphorylation sites from 285 proteins in a non-transformed human mammary epithelial cell (HMEC) line [@pone.0013587-Heibeck1]. From the 98 proteins that showed CSF-1R-induced or CSF-1R-induced\* tyrosine phosphorylation ([Table 1](#pone-0013587-t001){ref-type="table"}), there was a 51% (50/98) overlap with EGFR-induced phosphorylated proteins in HMECs ([Figure 2B](#pone-0013587-g002){ref-type="fig"}, [Table S5](#pone.0013587.s005){ref-type="supplementary-material"}). A number of the overlapping proteins (ERK1, ERK2, IRS2, GAB1, SHB, SHC and PI3K p85-alpha) are key signaling intermediates for multiple signaling pathways. The CSF-1R and EGFR pathways also overlap in their regulation of cellular adhesion through the phosphorylation of p120-catenin (p120), cofilin, plakophilin 3, pyk2, talin and integrin β4. Therefore, CSF-1R induces tyrosine phosphorylation of many proteins that are also regulated by EGFR.

Due to the frequent activation/over-expression of ERBB2/HER2 in mammary epithelial tumors, we also examined the overlap between CSF-1R-induced changes in tyrosine phosphorylation and changes induced by this RTK. Phosphoproteomic analysis of tyrosine-phosphorylated proteins in ERBB2-overexpressing breast and ovarian cancer cell lines identified 78 proteins with increased phosphorylation [@pone.0013587-Mukherji1], 12 of which overlapped with the CSF-1R- induced and CSF-1R induced\* proteins (p120, EPHA2, ACK, integrin β4, HGF-R, KIRREL, caveolin-1, EGFR, GAB1, CDC2, PI3-K p85 alpha, and ERK2). In a similar analysis, Bose and colleagues identified 198 proteins with increased tyrosine phosphorylation in ERBB2-over-expressing NIH-3T3 cells using a quantitative MS approach [@pone.0013587-Bose1]; only 19 of these overlap with the CSF-1R induced and CSF-1F induced\* proteins (annexin A2, β-adaptin, ARP2/3 subunit 3, calmodulin, caveolin, cct-theta, p120, PI3K p85-beta, intersectin 2, LDH-A, PGK1, PKM2, PI3K p85-alpha, PTRF, vimentin, HSP90-β, glutathione-S-transferase, RAN and YES). The lack of extensive overlap with CSF-1R-induced phosphoproteins in both ERBB2 studies could in part reflect cell-type differences (fibroblasts vs. mammary epithelial), species differences (mouse vs. human), and differing receptor activities (ERBB2 vs. CSF-1R). It is also possible that under-sampling contributes to the disparities between the studies due to the nature of MS-based studies.

We identified three proteins with increased tyrosine phosphorylation in all the proteomic datasets. CSF-1R, EGFR and ERBB2 activation all increase the tyrosine phosphorylation of p120, caveolin and PI3-K p85-alpha, suggesting that they are key common substrates of RTK activation. In addition, phosphorylation of ACK, calmodulin, EPHA2, integrin β4, intersectin 2, KIRREL, HGF-R, GAB1, CDC2, ERK2, annexin A2, and PI3-K p85-beta were induced by CSF-1R and identified in at least one of the other three proteomic datasets analyzed for RTK-induced tyrosine phosphorylation indicating that their phosphorylation is not unique to CSF-1R.

From the comparative analysis, we determined that 35 of the CSF-1R induced phosphoproteins did not overlap with those identified in any of the analyzed RTK studies ([Table 4](#pone-0013587-t004){ref-type="table"}). Of these 35 proteins, we were able to link 16 of these proteins to the CSF-1R pathway using Ingenuity IPA, a database of protein-protein interactions curated from the literature, allowing one or two intermediate signaling proteins. However, the remaining 19 of these proteins including ACLY, CNP, UBXD8, GUK 1, H2B1L, H2B2E, LDH-B, KIAA0323, NHP2L1, PDLIM5, PIN4, RPS27, SLC20A1, STEAP1, TAOK1, TJAP1, urdpase1, UQCRC2, and ZDHHC7 could not be linked to the CSF-1R pathway and thus represent novel CSF-1R targets ([Table 4](#pone-0013587-t004){ref-type="table"}). Many of these proteins are not well characterized, and thus could lead to new insights into the biological consequences of CSF-1R activity in epithelial cells and its role in epithelial tumorigenesis.

10.1371/journal.pone.0013587.t004

###### Proteins with increased tyrosine phosphorylation unique to CSF-1R.
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  Protein Name             UniProt \#   NCBI Site            Classification
  ----------------------- ------------ ----------- -----------------------------------
  TAOK1                      Q7L7X3       Y309               CSF-1R induced
  UBXD8                      Q96CS3        Y79               CSF-1R induced
  UQCRC2                     P22695       Y207               CSF-1R induced
  SPG20                      Q8N0X7        Y46       CSF-1R induced\*, Src-dependent
  ADK2                       P54819       Y199      CSF-1R induced\*, Src-independent
  D-PROHIBITIN               Q99623       Y121      CSF-1R induced\*, Src-independent
  GUK1                       Q16774        Y52      CSF-1R induced\*, Src-independent
  KRT81                      Q14533       Y282      CSF-1R induced\*, Src-independent
  LDH-B                      P07195       Y239      CSF-1R induced\*, Src-independent
  PI3K p85-gamma             Q92569       Y373      CSF-1R induced\*, Src-independent
  STEAP1                     Q9UHE8        Y27      CSF-1R induced\*, Src-independent
  CDK3                       Q00526     T14, Y15     CSF-1R induced\*, Src-inhibited
  NDUFB10                    O96000        Y54       CSF-1R induced\*, Src-inhibited
  PI3-kinase p110 alpha      P42336       Y508       CSF-1R induced\*, Src-inhibited
  CSF-1R                     P07333       Y561        CSF-1R induced, Src-dependent
  FLJ20625                   Q9NWT0        Y40        CSF-1R induced, Src-dependent
  KIAA0323                   O15037       Y456        CSF-1R induced, Src-dependent
  TJAP1                      Q5JTD0       Y352        CSF-1R induced, Src-dependent
  ZDHHC7                     Q9NXF8       Y130        CSF-1R induced, Src-dependent
  INSULIN RECEPTOR           P06213       Y1189      CSF-1R induced, Src-independent
  PIN4                       Q9Y237       Y122       CSF-1R induced, Src-independent
  PKC Delta                  Q05655       Y374       CSF-1R induced, Src-independent
  RPS27                      P42677        Y31       CSF-1R induced, Src-independent
  ACLY                       P53396       Y1073       CSF-1R induced, Src-inhibited
  CNP                        P09543       Y110        CSF-1R induced, Src-inhibited
  DLG1                       Q12959       Y760        CSF-1R induced, Src-inhibited
  Enolase 1                  P06733       Y188        CSF-1R induced, Src-inhibited
  H2B1L                      Q99880        Y42        CSF-1R induced, Src-inhibited
  H2B2E                      Q16778        Y43        CSF-1R induced, Src-inhibited
  HGK                        O95819       Y1227       CSF-1R induced, Src-inhibited
  NHP2L1                     P55769        Y31        CSF-1R induced, Src-inhibited
  PDLIM5                     Q96HC4       Y251        CSF-1R induced, Src-inhibited
  SLC20A1                    Q8WUM9       Y388        CSF-1R induced, Src-inhibited
  UrdPase 1                  Q16831        Y35        CSF-1R induced, Src-inhibited
  VASP                       P50552        Y38        CSF-1R induced, Src-inhibited

Y561-dependent, putative SRC-dependent, changes in tyrosine phosphorylation {#s2d}
---------------------------------------------------------------------------

To identify putative SRC targets, we examined whether the detected changes in tyrosine phosphorylation are dependent on Y561 by comparing the phosphotyrosine profile of cells expressing the CA-CSF-1R Y561F mutant, which is unable to recruit SRC, to that of cells expressing the CA-CSF-1R. For the CA-CSF-1R/CA-CSF-1R Y561F comparison, fold change ratios \>1.55 were defined as an upregulation in the levels of tyrosine phosphorylation, ratios 0.63--1.55 as unchanged, and ratios \<0.63 as a downregulation of tyrosine phosphorylation (See [Materials and Methods](#s4){ref-type="sec"} and [Table S3](#pone.0013587.s003){ref-type="supplementary-material"}). As Y561 is not exclusively selective for SRC, we cannot distinguish SRC substrates from those of other SFKs, and thus all peptides specifically detected in the CA-CSF-1R Y561F expressing cells are not necessarily exclusively SRC-regulated. It is also possible that other proteins in addition to SRC family kinases can bind to this site; however, we will refer to the Y561-dependent changes as SRC-dependent for simplicity of nomenclature. Tyrosine phosphorylated peptides were found to fall into three different categories based on the Y561 site: "SRC-independent" sites displayed no differences in tyrosine phosphorylation between CA-CSF-1R and CA-CSF-1R Y561F cells; "SRC-dependent" sites demonstrated an increase in tyrosine phosphorylation in CA-CSF-1R cells compared to CA-CSF-1R Y561F cells; and "SRC-inhibited" sites showed higher phosphorylation in the CA-CSF-1R Y561F cells as compared to CA-CSF-1R cells ([Table 1](#pone-0013587-t001){ref-type="table"}, [Table S3](#pone.0013587.s003){ref-type="supplementary-material"}).

Earlier studies have demonstrated that the CSF-1R Y561F mutation impairs the ligand-dependent auto-phosphorylation of CSF-1R; however, the Y561F mutation did not compromise the auto-phosphorylation of CA-CSF-1R in this analysis as both the activation loop residue, Y809, and Y873 had equal levels of tyrosine phosphorylation between CA-CSF-1R and CA-CSF-1R Y561F [@pone.0013587-Marks1], [@pone.0013587-Rohde1]. Equal levels of phosphorylation were also detected at the Grb2 binding site, Y699, and Y923, supporting the conclusion that the total kinase activity of CSF-1R was not significantly affected by the Y561F mutation ([Table S3](#pone.0013587.s003){ref-type="supplementary-material"}). In addition, our previous data indicates that the CA-CSF-1R Y561F is equally competent for signaling as it can induce growth factor independence in MCF-10A cells and promote MCF-10A acini growth similar to CA-CSF-1R [@pone.0013587-Wrobel1]. The previously reported defects in autophosphorylation may not be relevant in the context of the active variant of the receptor in which point mutations permit ligand-independent receptor activation and inhibit the receptor downregulation via internalization.

Quantitative comparison of the differences in peptide tyrosine phosphorylation between CA-CSF-1R and CA-CSF-1R Y561F-expressing cells identified 22 tyrosine sites on 19 proteins dependent on CA-CSF-1R Y561 that were phosphorylated above threshold (ratio \>1.55, see [Materials and Methods](#s4){ref-type="sec"}) ([Table 5](#pone-0013587-t005){ref-type="table"}). Although phosphorylation of SRC at its activation site (Y418) was not detected in cells expressing either form of CSF-1R, CA-CSF-1R was highly phosphorylated at Y561 indicating that this site is competent to recruit and activate SRC. In addition, known SRC targets including p120, ACK, and Hrs demonstrated a Y561-dependent increase in phosphorylation. β-adaptin, intersectin 2, and KIAA1217 were also identified as having SRC-dependent tyrosine phosphorylation sites. Furthermore, this analysis provided supporting evidence of Src regulation of the following sites: Integrin β4 Y1510, FLJ20625 Y40, Hrs Y334, TJAP1 Y352 and ZDHHC7 Y130. These sites were identified as SRC-dependent in CA-CSF-1R expressing MCF-10A cells in a previous non-quantitative LC-MS/MS study (data not shown, [Figure 3C](#pone-0013587-g003){ref-type="fig"}).

![Y561-dependent changes in phosphorylation are SRC-dependent changes in tyrosine phosphorylation.\
**A**) pLOGos representation of motif extracted from the SRC dependent substrates identified in the quantitative MS analysis. Also shown are motif representations generated from collections of known SRC targets in PhosphoSite® Plus, Phospho.ELM and ScanSite, respectively. **B**) GeneGO® enrichment analysis of the SRC-dependent proteins using the \>1.32 inclusive threshold. **C**) Validation of SRC-dependent differential tyrosine phosphorylation detected in a pilot qualitative MS analysis by quantitative MS analysis. Because the pilot experiments did involve the isotopic labeling of cellular proteins, the qualitative MS analysis was designed only to detect the presence of tyrosine phosphorylated peptides isolated by phosphotyrosine immunoprecipitation. **D**) Western blot analysis of SRC, Stat5 and Hrs tyrosine phosphorylation. Lysates from CA-CSF-1R cells treated with either vehicle control or the SRC kinase inhibitor, SU6656, were analyzed for changes in tyrosine phosphorylation using phospho-specific antibodies for SRC Y418 and Stat5 Y694. Hrs immunoprecipitates from Parental, CA-CSF-1R and CA-CSF-1R Y561F MCF-10As were probed with a phosphotyrosine antibody.](pone.0013587.g003){#pone-0013587-g003}

10.1371/journal.pone.0013587.t005

###### SRC-dependent tyrosine phosphorylated peptides identified in the comparison of CA-CSF-1R to CA-CSF-1R Y561F MCF-10A cells.
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  Protein Name     NCBI Site              Peptide Sequence             Fold change                   Function
  --------------- ------------ -------------------------------------- ------------- ------------------------------------------
  CSF-1R              Y561      K.IIESYEGNSY\#TFIDPTQLPYNEK∧WEFPR@.N     \>16.44             Receptor tyrosine kinase
  p120catenin         Y904               K.SLDNNY\#STPNER.G               5.31                       Adhesion
  Hrs                 Y132          K.VVQDTY\#QIMK∧VEGHVFPEFK∧.E          5.06                   Adaptor/scaffold
  Hrs                 Y334               <R.YLNR@NY#WEK>∧.K               4.49                   Adaptor/scaffold
  TJAP1               Y352              <R.NSPLPNCTY#ATR@.Q>              4.31                       Adhesion
  ZDHHC7              Y130            K.EYMESLQLK∧PGEVIY\#K∧.C            4.05                   Unknown function
  ZDHHC7              Y130            K.EYMESLQLK∧PGEVIY\#K∧.C            3.99                   Unknown function
  ZDHHC7              Y130           K.EYMESLQLKPGEVIY\#KCPK.C            3.98                   Unknown function
  Hrs                 Y216               R.VCEPCY\#EQLNR.K                3.51                   Adaptor/scaffold
  Hrs                 Y216              <R.VCEPCY#EQLNR@.K>                3.5                   Adaptor/scaffold
  Ack                 Y518           K.KPTY\#DPVSEDQDPLSSDFKR.L           3.45               Protein tyrosine kinase
  Hrs                 Y132               K.YKVVQDT\#YQIMK.V               3.12                   Adaptor/scaffold
  Hrs                 Y132               K.VVQDTY\#QIMK∧.V                3.11                   Adaptor/scaffold
  Intersectin 2       Y552                 K.LIY\#LVPEK.Q                 2.73                   Adaptor/scaffold
  Hrs                 Y132              K.YK∧VVQDTY\#QIMK∧.V              2.63                   Adaptor/scaffold
  ATP1A1              Y260                R.GIVVY\#TGDR.T                 2.62                      Hydrolase
  KIAA0323            Y456          R.HIVIDGSNVAMVHGLQHY\#FSSR.G          2.22                   Unknown function
  Beta-adaptin        Y276               K.DSDY\#YNMLLK∧.K                2.12                   Vesicle protein
  Stat 5A             Y694               K.AVDGY\#VKPQIK.Q                2.11                 Transcription factor
  EphA2               Y575               R.QSPEDVY\#FSK∧.S                2.11               Receptor tyrosine kinase
  EphB4            T587, Y595   K.HGQYLIGHGT\#KVYIDPFTY\#EDPNEAVR.E       2.09               Receptor tyrosine kinase
  FLJ20625            Y40             <K.ALNGAEPNY#HSLPSAR@.T>            2.06                   Unknown function
  KIAA0323            Y456         <R.HIVIDGSNVAMVHGLQHY#FSSR@.G>         1.98                   Unknown function
  RAN                 Y146                K.NLQY\#YDISAK.S                1.81       Nuclear receptor co-regulator, G protein
  PLEKHA6             Y492             <R.SEDIY#ADPAAYVMR@.R>             1.79                Lipid binding protein
  EphB4               Y774          R.FLEENSSDPTY\#TSSLGGKIPIR.W          1.75               Receptor tyrosine kinase
  KIAA0323            Y456        R.HIVIDGSNVAM\*VHGLQHY\#FSSR@.G          1.7                   Unknown function
  SPG20               Y46             K.GLNTDELGQKEEAKNYY\#K.Q            1.66                   Unknown function
  KIAA1217            Y393             R.NEGFY\#ADPYLYHEGR.M               1.6                   Unknown function
  Integrin β4        Y1510       <R.SEHSHSTTLPR@DY#STLTSVSSHDSR@.L>       1.59                  Adhesion, Receptor

\# indicates phosphorylation.

\* indicates oxidation.

@ indicates "heavy" arginine.

∧ indicates "heavy" lysine.

53% (171/324) of the peptides detected in the CA-CSF-1R vs. CA-CSF-1R Y561F comparison were classified as SRC-independent ([Table S2](#pone.0013587.s002){ref-type="supplementary-material"}). Multiple sites on proteins associated with focal adhesions were phosphorylated in a SRC-independent manner, including paxillin Y88, Y118, FAK Y576, p130Cas Y128, Y234, Y267, Y249, Y327, Y387, talin Y70 and integrin β4 Y1207. Since many of these are known targets of SRC, it is likely that SRC molecules activated by integrin receptor engagement, rather than SRC recruitment to CSF-1R, are responsible for these phosphorylation events.

35% (112/324) of peptides detected were classified as SRC-inhibited ([Table S2](#pone.0013587.s002){ref-type="supplementary-material"}). These peptides contained sites that displayed elevated levels of phosphorylation in CA-CSF-1R Y561F-expressing cells, raising the possibility that SRC/SFKs may negatively regulate these sites. Proteins with phosphorylated tyrosine sites that were higher in the Y561F mutant-expressing cells included caveolin, vimentin, DLG1, and DLG3, among others ([Table S3](#pone.0013587.s003){ref-type="supplementary-material"}). One possible explanation for this finding is that SRC activates a phosphatase that targets these proteins. Alternatively, it is possible that CSF-1R-induced changes in cellular adhesion could alter the localization of SRC modifying its access to specific substrates and thus leading to distinct patterns of tyrosine phosphorylation dependent on the Y561 site.

Motif analysis of SRC-regulated peptides {#s2e}
----------------------------------------

To determine whether the peptides that exhibited putative SRC-dependent phosphorylation sites were enriched for specific sequences flanking the tyrosine phosphoacceptor, we utilized an on-line extraction algorithm, Motif-X (motif-x.med.harvard.edu), developed by Schwartz and Gygi [@pone.0013587-Schwartz1], [@pone.0013587-Songyang1]. This algorithm identifies the most frequently occurring residues in positions surrounding the pY and provides statistical information on the significance of their repeated appearance. To identify enriched amino acid sequences in the detected phosphopeptides, peptide sequences were centered around the phosphorylated tyrosine residue, and the significance threshold was set to p\<0.0001 with a minimum number of occurrences for a particular sequence set to four because of the relatively small number of peptides analyzed. Because of the limited number of SRC-dependent peptides, we included all peptides with fold change values within one standard deviation of the mean (\>1.32). While statistically the detected changes in phosphorylation of peptides with fold change values 1.32--1.55 are less likely to be significant, this set of peptides includes known SRC targets such as p120 and p130Cas, supporting the hypothesis that such peptides may in fact be regulated by CSF-1R-induced SRC activation.

The extracted motif as shown in [Figure 3A](#pone-0013587-g003){ref-type="fig"} very closely resembles the previously identified consensus c-SRC kinase substrate motif, D \[ED\] \[EDG\] \[IVL\] Y\# \[GE\] E \[FI\] F [@pone.0013587-Songyang1]. Recent work by Schwartz and colleagues has led to the development of more informative sequence motif representation using Motif-X pLOGos (probability log-based logos) (Schwartz, Chou and Church, unpublished data). Residues closest to the midline in the pLOGos motif representation have the greatest degree of correlation. Those residues above the midline are overrepresented while those below the midline are underrepresented. The red line indicates a p\<0.01. The height of the residue symbol is proportional to the correlation values of the residue at that position, and fixed positions within the sequence are indicated with only one residue.

The motif analysis identified a high selectivity for proline at the +3 position in the SRC-dependent phosphopeptides. Peptides derived from p120, p130Cas, STAT5A, EPHA2, KIAA1217 and ZDHHC7 have a proline at the +3 position. pLOGos representations of SRC consensus motifs derived from annotated substrates in the databases PhosphoSitePlus®, Phospho.ELM and Scansite are shown in [Figure 3A](#pone-0013587-g003){ref-type="fig"} [@pone.0013587-Hornbeck1], [@pone.0013587-Obenauer1]. The same preference for a hydrophobic residue at the +3 position appears in each of these motifs. Interestingly, Schwartz and Gygi uncovered this same preference in an analysis of two phosphotyrosine proteomic data sets generated by pervanadate-induced phosphorylation in Jurkat cells and c-SRC Y527F-stimulated phosphorylation in NIH-3T3 cells [@pone.0013587-Rush1], [@pone.0013587-Schwartz1]. The SRC consensus representations also clearly indicate a preference for acidic residues at positions −4, −3, −2, and +1; the motif extracted from the CSF-1R-induced SRC substrates has the same profile. Thus, while the nature of this study does not allow us to distinguish between direct and indirect SRC substrates, this motif analysis of the Y561-dependent phosphorylation sites suggest that many are in fact direct SRC substrates since the most prominent sequence motif closely matches known c-SRC consensus motifs [@pone.0013587-Schwartz1], [@pone.0013587-Songyang1]. In addition, the motif analysis validated the inclusion of phosphopeptides with fold change values 1.32--1.55 and provided evidence that these sites may be SRC regulated since many closely match the SRC consensus motif.

Enrichment Analysis of the SRC-dependent peptides {#s2f}
-------------------------------------------------

To derive information on the cellular functions of the SRC-dependent substrates, we performed an enrichment analysis. This analysis included all SRC-dependent phosphorylated proteins with a fold change \>1.32 ([Table S2](#pone.0013587.s002){ref-type="supplementary-material"}). Three of the cellular processes found to be overrepresented in this set of substrates were related to some aspect of cell adhesion including the regulation of cell junctions and cadherins ([Figure 3B](#pone-0013587-g003){ref-type="fig"}). The enrichment identified p120, plakophilin 4, erbin, EPHA2, EPHB4, and PIK3R3 as proteins associated with the regulation of cell junctions and cadherins; these proteins may be candidate mediators of the CSF-1R-induced SRC-dependent adhesion disruption.

Validation of differential tyrosine phosphorylation {#s2g}
---------------------------------------------------

While it wasn\'t feasible to validate a large number of tyrosine phosphorylation sites identified in this screen, six of the proteins identified in the SILAC analysis overlap with SRC-dependent substrates identified in a pilot, non-quantitative MS analysis ([Figure 3C](#pone-0013587-g003){ref-type="fig"} and data not shown). We also validated the SRC-induced tyrosine phosphorylation of two substrates, Hrs and STAT5A ([Figure 3D](#pone-0013587-g003){ref-type="fig"}). CA-CSF-1R-expressing MCF-10As were treated with the SRC kinase inhibitor, SU6656, overnight prior to analysis. Treatment with the inhibitor decreased phosphorylation of the SRC active site (Y418) ([Figure 3D](#pone-0013587-g003){ref-type="fig"}), validating the efficacy of the inhibitor. Tyrosine phosphorylation of STAT5A Y694 was reduced in the SU6656-treated CA-CSF-1R cells, and the CSF-1R Y561F did not induce phosphorylation of the site. In addition, we observed that tyrosine phosphorylation of Hrs was not induced by the CSF-1R Y561F. While we were unable to define which sites on Hrs were phosphorylated, this evidence validates that phosphorylation of this protein is SRC-dependent.

Analysis of tyrosine phosphorylation in human cancer phosphoproteomic datasets {#s2h}
------------------------------------------------------------------------------

To address the relevance of the identified SRC substrates to tumorigenesis, we conducted comparative bioinformatics analysis on phosphoproteomic datasets generated from human tumor samples. Because we profiled CSF-1R-induced and SRC-dependent changes in tyrosine phosphorylation in a mammary epithelial cell line, we first analyzed a small breast cancer dataset, derived from only eight tumors, available publicly from CST\'s PhosphoSitePlus® [@pone.0013587-Hornbeck1]. Many SRC-dependent sites identified in our study were tyrosine phosphorylated in these human breast tumors ([Table 6](#pone-0013587-t006){ref-type="table"}). The small size of the dataset and the detection of activated SRC in all eight tumors precluded a rigorous correlation analysis between SRC activation and substrate phosphorylation. However, several putative SRC substrates, including HIPK3, STAT5A, p120, FRK and Hrs, were frequently phosphorylated in multiple breast tumors.

10.1371/journal.pone.0013587.t006

###### Comparative analysis of tyrosine phosphorylation detected in human breast tumors.

![](pone.0013587.t006){#pone-0013587-t006-6}

  Protein Name    NCBI site   Fold change (CA-CSF1R/Y561F)   \# of tumors   Tumors[\*](#nt106){ref-type="table-fn"} with phosphorylation
  -------------- ----------- ------------------------------ -------------- --------------------------------------------------------------
  Src               Y418                   \-                     8                            1, 2, 3, 4, 5, 6, 7, 8
  HIPK3              359                  1.43                    8                            1, 2, 3, 4, 5, 6, 7, 8
  STAT5A             694                  2.11                    7                             2, 3, 4, 5, 6, 7, 8
  p120catenin        904                  5.31                    6                               1, 2, 4, 5, 6, 8
  Hrs                216                  3.51                    5                                1, 3, 4, 5, 8
  Frk                46                   1.41                    5                                1, 3, 6, 7, 8
  Ack                518                  3.45                    4                                  1, 4, 5, 6
  Hrs                132                  5.06                    2                                     2, 4
  ATP1A1             260                  2.62                    1                                      2
  p120catenin        228                  1.53                    1                                      2

\***Tumor\# PhosphoSite Plus® ID.**

1  BC0001.

2  BC0002.

3  BC0003.

4  BC0004.

5  BC0005.

6  BC0007.

7  BC0008.

8  csBC0001.

Given the limited amount of phosphotyrosine proteome data available from breast tumor dataset, we also analyzed a larger set of phosphoproteomic data derived from human non-small cell lung cancer. Rikova and colleagues analyzed the phosphorylation of proteins in 150 human NSCLC lung tumors using PhosphoScan® analysis [@pone.0013587-Rikova1]. Activating mutations of *EGFR* are frequently found in NSCLC tumors, and EGFR activation can similarly induce the upregulation of endogenous c-SRC. We performed correlation studies to determine the substrates whose phosphorylation significantly correlated with SRC activity based on detection of the phosphorylation of Y418 SRC autophosphorylation site.

The comparison revealed that many SRC-dependent proteins were also tyrosine phosphorylated in human lung tumors. Five proteins (p120, p130Cas, FRK, Hrs and KIAA0323) showed a significant correlation (p-value\<0.05) between SRC activation and tyrosine phosphorylation ([Table 7](#pone-0013587-t007){ref-type="table"}). Three of these five proteins (p120, Hrs, and FRK) were also commonly tyrosine phosphorylated in the human breast cancer dataset. This finding of significant co-regulation of SRC activity and substrate phosphorylation indicate that these may be critical SRC substrates in the context of a human epithelial tumor. Together, our analyses suggest that a subset of the SRC-dependent substrates we identified downstream of CSF-1R induced SRC activation are relevant in human epithelial tumorigenesis. Substrates such as p120, Hrs, Ack, p130Cas and FRK may be key mediators of SRC signaling in human tumors and contribute directly to SRC-mediated events during tumor progression.

10.1371/journal.pone.0013587.t007

###### Comparative analysis of tyrosine phosphorylation detected in human lung tumors.

![](pone.0013587.t007){#pone-0013587-t007-7}

  Protein Name    NCBI Site   Fold change (CA-CSF-1R/Y561F)   p-Value
  -------------- ----------- ------------------------------- ----------
  p130Cas           Y234                  1.37                0.001993
  p120catenin       Y228                  1.53                0.004847
  p120catenin       Y904                  5.31                0.013537
  Frk                Y46                  1.41                0.017747
  Hrs               Y216                   3.5                0.021389
  KIAA0323          Y502                  2.22                0.037628

Discussion {#s3}
==========

The quantitative MS analysis performed in this study identified proteins phosphorylated downstream of CSF-1R activation in mammary epithelial cells and defined a specific set of these proteins as candidate targets of SRC family kinases. While earlier studies have identified CSF-1R and SRC targets phosphorylated in other cell types, some of which were detected in this analysis, previously unrecognized targets of these kinases were also revealed in this study. Comparative analysis with other RTK tyrosine phosphoproteomic datasets revealed multiple overlapping pTyr substrates in CSF-1R-, EGFR- and ERBB2-expressing cells and highlighted the shared regulation of caveolin, p120 and PI3-K by these RTK pathways. Many of the putative SRC substrates including p120, Hrs and STAT5A are likely direct SRC targets based on the degree of overlap between the peptides detected and the known SRC consensus motif, as well as the observed downregulation of tyrosine phosphorylation by pharmacological inhibition of SRC kinase activity. In addition, the phosphorylation of several SRC substrates significantly correlated with SRC activation in human lung tumors. Substrates that correlated with SRC activation, such as p120, Hrs, p130Cas, FRK and KIAA0323, may be critical mediators of SRC activity in human tumors.

CSF-1R signaling {#s3a}
----------------

The CSF-1 pathway is required for macrophage differentiation and survival, yet previous work suggests the CSF-1 pathway may also drive tumor cell progression. Our data delineate the changes in tyrosine phosphorylation induced by CSF-1R signaling in epithelial cells. Unlike substrates of EGFR and ERBB2, CSF-1R targets in epithelial cell have not been well characterized. Like other growth factor receptor tyrosine kinases, CSF-1R induces pleiotropic phenotypic alterations in epithelial cells. CSF-1R activation in MCF-10A cells induces cell-cell adhesion disruption, loss of contact inhibition, growth in soft agar, and enhanced cell motility [@pone.0013587-Wrobel1], [@pone.0013587-Gunawardane1]. In addition, recent studies showed that invasion by a human breast tumor cell line is dependent on paracrine signaling with host macrophages as well as autocrine signaling involving CSF-1R expressed on tumor cells themselves [@pone.0013587-Patsialou1]. The candidate substrates identified in our analysis (e.g. p120, integrin β4, plakophilin 3, STAT3 and vimentin) will inform future studies addressing the mechanisms involved in CSF-1R-induced tumor progression.

Using comparative bioinformatic analysis, we found that CSF-1R modified a set of proteins which did not overlap with those phosphorylated downstream of other RTKs e.g., EGFR and ERBB2. From this set of 35 proteins, we identified 19 proteins, which had not been previously linked to CSF-1 signaling based on studies published to date; these proteins may represent substrates unique to CSF-1R signaling. These proteins regulate a number of different cellular processes including trafficking, cell cycle progression and cell polarity and exhibit such diverse functions as kinases, adaptors and structural proteins. Many of these proteins are not well characterized; thus studies of these putative novel targets may reveal new mechanistic insights into epithelial cell biology and tumorigenesis. For example, two of these proteins, ACLY and UQCRC2, play a role in the regulation of cellular metabolism. ACLY, ATP citrate lyase, is an enzyme involved in the conversion of glucose to cytosolic acetyl CoA, which is a part of the glucose-dependent lipogenesis pathway [@pone.0013587-Yancy1], [@pone.0013587-Migita1]. UQCRC2, ubiquinol-cytochrome C reductase complex III protein 2, is a protein involved in oxidative phosphorylation and is a subunit of the mitochondrial cytochrome bc1 complex. Cancer cells undergo changes in metabolism in order to shift to the metabolic demands of proliferative cells [@pone.0013587-Weinberg1], [@pone.0013587-Pan1]. Interestingly, ACLY can be phosphorylated and activated by Akt [@pone.0013587-Berwick1]. Upregulation of ACLY activity in tumor cells expressing activated Akt could suppress fatty acid oxidation (through increased acetyl-CoA and malonyl-CoA production), thus supporting the significant requirement for lipid synthesis in proliferative cell states. Serine phosphorylation of ACLY in non-small cell lung cancer cell lines has been shown to upregulate ACLY activity and siRNA-mediated KD of the protein induces growth arrest [@pone.0013587-Migita1]. ACLY expression is increased in metastatic breast cancer lines in comparison to non-tumorigenic and non-metastatic cell lines [@pone.0013587-Yancy1]. These data could suggest a role for ACLY in breast metastasis and its phosphorylation in the regulation of protein function. In our study, CSF-1R activation induced a 26-fold increase in tyrosine phosphorylation of ACLY at Y1073. Our data may reveal new insights into the regulation of ACLY by tyrosine phosphorylation. Similarly, UQCRC2 levels are altered in cancer cells, showing a decrease in mitochondria from breast cancer cells as compared to normal breast cells [@pone.0013587-Putignani1]. Since we detected a 10-fold increase in CSF-1R-dependent phosphorylation of UQCRC2, this raises that possibility that this modification may downregulate it\'s activity, thus causing a similar loss of activity as observed in tumor cells with lower levels of UQCRC2 expression. The changes in tyrosine phosphorylation on proteins involved in metabolism highlight candidate effectors that may contribute to altered metabolism in CSF1-1R-driven phenotypes.

CSF-1R-induced, SRC substrates {#s3b}
------------------------------

As the first characterized proto-oncogene, SRC has been extensively studied in human tumors; however, SRC itself is not frequently mutated, and on its own is not strongly transforming. The increased activation of SRC detected in tumor cells may therefore result from upstream activated RTKs [@pone.0013587-Bromann1]. CSF-1R-induced SRC activation may mimic the upregulation of SRC activity by RTKs in human tumors. Therefore, CSF-1R-induced SRC-dependent substrates are likely more relevant to tumorigenesis than substrates of overexpressed c-SRC or activated mutants of the protein. Surprisingly, comparison of SRC substrates identified in our study to SRC targets identified in other MS-based studies revealed relatively small overlap (data not shown) [@pone.0013587-Amanchy1], [@pone.0013587-Rush1], [@pone.0013587-Leroy1], [@pone.0013587-Luo1], [@pone.0013587-Amanchy2]. This may be due to the use of overexpressed or constitutively active SRC in these studies, which may lead to phosphorylation of a broader set of substrates distinct from those targeted by RTK-induced SRC activity. SRC can be activated by multiple classes of membrane receptors, such as G protein-coupled receptors, cell adhesion molecules, and integrins. Overexpression of wild-type or activated SRC mutants may induce phosphorylation of this broader subset of targets distinct from the substrates of endogenous c-SRC activated by an upstream growth factor receptor.

SRC activity and substrate phosphorylation is tightly controlled in vivo by intramolecular interactions and protein localization, and such regulatory mechanisms are disrupted in SRC mutant variants [@pone.0013587-Thomas1]. In our study, endogenous wild-type SRC was activated by an upstream RTK, more closely reflecting the effects of activation of endogenous SRC in tumor cells. Thus, our experimental design facilitated the selective identification of targets most likely regulated by RTK-activated SRC. Furthermore, we identified five proteins whose phosphorylation was significantly associated with SRC activation in human lung tumors. Of these five proteins, p120, Hrs and FRK may be particularly relevant to SRC-driven tumor progression. The SRC-related tyrosine kinase, FRK, was recently demonstrated to act as tumor suppressor by attenuating AKT/PI3Kinase signaling through its action on the phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase, PTEN [@pone.0013587-Yim1]. FRK-mediated phosphorylation of PTEN blocks its interaction with an E3 ubiquitin ligase and stabilizes PTEN protein. The siRNA-mediated knockdown of FRK in MCF-10A cells resulted in depletion of PTEN, and its loss was sufficient to cause transformation [@pone.0013587-Brauer1]. As such, our finding of a significant correlation between SRC activity and FRK tyrosine phosphorylation in human lung tumors raises the possibility that SRC-mediated phosphorylation of FRK may negatively regulate FRK functions.

CSF-1R-SRC-induced adhesion disruption -- regulators of E-cadherin surface stability {#s3c}
------------------------------------------------------------------------------------

Our study aimed to define the CSF-1R induced, SRC-regulated proteins in part to identify candidate SRC substrates that may regulate cell adhesion in MCF-10A cells [@pone.0013587-Wrobel1]. RTK-induced SRC activation may also be responsible for the regulation of specific human tumor phenotypes such as cell invasion and motility, which can increase the metastatic potential of a tumor, as SRC targets substrates involved in the processes of cellular adhesion and migration [@pone.0013587-Frame1]. Elevated SRC activity is associated with invasiveness in colon tumors, suggesting that SRC induces cellular changes that promote tumor progression [@pone.0013587-Summy1]. A key component of invasive potential is the downregulation of cell-cell adhesion and the adhesive strength of adherens junctions (AJs), which can be accomplished by reducing surface expression of E-cadherin [@pone.0013587-Yap1]. The oncogenic mutant v-SRC can induce the downregulation of E-cadherin from the plasma membrane through tyrosine phosphorylation and ubiquitination, leading to E-cadherin degradation in lysosomes [@pone.0013587-Palacios1], [@pone.0013587-Fujita1]. However, our previous work revealed that E-cadherin levels do not decrease in the presence of SRC activation by CSF-1R in MCF-10As, but rather E-cadherin is redistributed to intracellular vesicles. Thus, we hypothesized that E-cadherin is sequestered in the cytoplasm following CSF-1R induction of SRC activity [@pone.0013587-Wrobel1].

p120 likewise regulates the stability of E-cadherin and is a well-characterized SRC target [@pone.0013587-Reynolds1]. In our study, CSF-1R induced the tyrosine phosphorylation of p120 Y904 and Y228 in a SRC-dependent manner ([Table 5](#pone-0013587-t005){ref-type="table"}). Given the evidence that p120 is a key regulator of cadherin stability and localization, these phosphorylation events may be critical to the regulation of p120 function and activity. p120 has multiple tyrosine residues that can be modified by SRC; yet the functional consequences of phosphorylation on p120 function are not well understood [@pone.0013587-Davis1], [@pone.0013587-Alema1]. We observed a difference in the relative increase of SRC-dependent phosphorylation between Y904 (5.31 fold increase) and Y228 (1.53 fold). Little is known about the significance of phosphorylated Y904, however, it has been detected in multiple whole-cell MS-based analyses (PhosphoSite, <http://www.phosphosite.org/home>). siRNA-mediated depletion of p120 dramatically disrupts cell-cell adhesion and reduces the levels of E-cadherin and associated proteins at AJs [@pone.0013587-Ireton1]. Similarly, CSF-1R activation of SRC leads to impaired cell-cell adhesion and re-localization of E-cadherin. As SRC phosphorylation of p120 correlates with disruption of MCF-10A adhesion, this modification may impair its function. SRC may further regulate p120 by modulation of the stoichiometry of p120 phosphorylation at specific sites.

Plakophilin 4, a p120 family member that exhibits cell type-dependent localization to AJs and desmosomes [@pone.0013587-Hatzfeld1], is also tyrosine phosphorylated downstream of CSF-1R activation in a SRC-dependent manner ([Table S2](#pone.0013587.s002){ref-type="supplementary-material"}). Overexpression of plakophilin 4 increases surface expression of classical cadherins, and plakophilin 4 functions similarly to p120 to stabilize cell-cell junctions by regulating E-cadherin [@pone.0013587-Reynolds1]. Intriguingly, plakophilin 4 interacts with erbin [@pone.0013587-Hatzfeld1], which also demonstrated increased phosphorylation at Y1104 in our study. Their coordinate phosphorylation may be involved in SRC regulation of cell-cell adhesion.

SRC may also influence the dynamics of cellular endocytosis indirectly leading to the downregulation of E-cadherin. Hrs, β-adaptin, and intersectin 2 demonstrated a SRC-dependent increase in tyrosine phosphorylation. These proteins have been previously shown to regulate distinct steps in endocytic trafficking [@pone.0013587-Pucharcos1], [@pone.0013587-Zimmerman1], [@pone.0013587-Raiborg1]. Hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) is an important regulator of protein sorting at the endosome. Residing at the cytoplasmic face of early endosomes and multivesicular bodies, Hrs interacts with multiple proteins such as clathrin and EPS15 in addition to mono- and poly-ubiquitinated proteins via its ubiquitin-interacting motif (UIM) [@pone.0013587-Raiborg1], [@pone.0013587-Raiborg2], [@pone.0013587-Raiborg3]. Palacios and colleagues further demonstrated that E-cadherin sorting to the lysosome requires an intact Hrs UIM, and E-cadherin was found to associate with Hrs in an ubiquitin-dependent manner [@pone.0013587-Palacios1]. As with p120, our data suggest that SRC regulation of Hrs may be complex, as multiple tyrosine residues within Hrs were modified and to varying levels.

SRC activation and substrates in human tumors {#s3d}
---------------------------------------------

Analysis of the overlap between substrates phosphorylated in our study and in human tumors defined a group of proteins that may be most relevant to Src activity in human cancers: HIPK3, STAT5A, p120, Hrs and FRK in human breast tumors, and p130Cas, p120, FRK, Hrs and KIAA0323 in human lung tumors. Each of these proteins has been previously implicated in cancer onset or progression, and our data suggest that their tyrosine phosphorylation may play a role in oncogenic changes. SRC activity in human tumors may further coordinate the phosphorylation of multiple substrates to mediate downstream phenotypes. For example, the coordinate phosphorylation of p120 and Hrs could be required to significantly impact E-cadherin surface stability and disrupt cell-cell adhesion. The identification of a critical set of SRC substrates may lead to the definition of a SRC signature that could serve as a molecular flag that SRC is active in a given tumor. Thus, while monitoring the phosphorylation of one or two SRC targets may not predict response to a clinical SRC inhibitor like dasatinib, phosphorylation of a collection of proteins may be a more useful predictor of efficacy.

Materials and Methods {#s4}
=====================

Chemicals and Antibodies {#s4a}
------------------------

Stable isotope containing amino acids ^13^C~6~-^15^N~2~-L-lysine and ^13^C~6~-^15^N~4~-L-arginine were purchased from Cambridge Isotope Labs (Andover, MA). Antibodies to SRC phospho-Y418, STAT5A phospho-Y694, and STAT5A, were purchased from Cell Signaling Technologies (Danvers, MA). The tubulin antibody was obtained from Abcam Inc. (Cambridge, MA), and the Hrs antibody was procured from Alexis Biochemicals/Enzo Life Sciences (Farmingdale, NY). SRC inhibitor, SU6656, (Calbiochem) was used at 2µM.

Cell culture and stable isotope labeling with amino acids in culture (SILAC) {#s4b}
----------------------------------------------------------------------------

CA-CSF-1R and CA-CSF-1R Y561F MCF-10A cells were generated using pMSCV human CSF-1R L301S/Y969F provided by O. Witte (University of California, Los Angeles, CA). The Y561F mutant receptor was generated previously by Carolyn Wrobel [@pone.0013587-Wrobel1]. MCF10A cells were grown in a DMEM/F12 based medium as described previously [@pone.0013587-Debnath1] supplemented with dialyzed horse serum and either "light" or "heavy" arginine and lysisne. Cells were labeled over the course of five passages in the labeling medium prior to analysis. Prior to lysis, cells were cultured overnight in MCF-10A growth medium supplemented with reduced (2%) serum and deficient for EGF. Cells were lysed (9M urea, 20mM HEPES pH 8.0, 2.5mM sodium pyrophosphoate, 1mM beta glycerophosphate, and 1mM sodium vanadate). The lysates were sonicated and cleared by centrifugation in preparation for protease digestion, phophotyrosine immunoprecipitation and tandem liquid chromatography mass spectrometry.

Phosphopeptide immunoprecipitation {#s4c}
----------------------------------

Phosphopeptides were prepared using PhosphoScan® Kit (Cell Signaling Technology).

Analysis by LC-MS/MS Mass Spectrometry {#s4d}
--------------------------------------

Peptides in the immunoprecipitation eluate (40 µl) were concentrated and separated from eluted antibody using Stop and Go extraction tips (StageTips) [@pone.0013587-Rappsilber1]. Peptides were eluted from the microcolumns with 1 µl of 60% MeCN, 0.1% TFA into 7.6 µl of 0.4% acetic acid/0.005% heptafluorobutyric acid (HFBA). The sample was loaded onto a 10 cm×75 µm PicoFrit capillary column (New Objective) packed with Magic C18 AQ reversed-phase resin (Michrom Bioresources) using a Famos autosampler with an inert sample injection valve (Dionex). The column was developed with a 45-min linear gradient of acetonitrile in 0.4% acetic acid, 0.005% HFBA delivered at 280 nl/min (Ultimate, Dionex). Tandem mass spectra were collected in a data-dependent manner with an LTQ ion trap mass spectrometer (ThermoFinnigan), using a top-ten method, a dynamic exclusion repeat count of 1, and a repeat duration of 10 sec. TurboSequest (ThermoFinnigan) searches were done against the NCBI human database released on August 24, 2004 (containing 27,175 proteins) allowing for tyrosine phosphorylation (Y+80) and oxidized methionine (M+16) as dynamic modifications. Sequence assignments were accepted based on the score-filtering criteria we described previously (Rush et al., 2005), except assignments that had the score characteristics of false-positive assignments, determined by searching against a database of reversed protein sequences [@pone.0013587-Peng1] were not accepted.

To guide our assignment of the threshold for significant fold changes phosphorylation, we first graphed the distribution of the non-phosphorylated peptides present in the immunoprecipitated samples and determined the mean of the quantitative fold change values. We assumed data normality based on these distributions; therefore, fold change values greater than two deviations from the mean are considered 95% likely to represent significant differences in tyrosine phosphorylation. Each comparison had a different mean value for the non-phosphopeptide distribution; however, the same statistical threshold was applied to both comparisons. For the CA-CSF-1R/parental MCF-10A comparison, fold change ratios \>1.94 were defined as an upregulation in the levels of tyrosine phosphorylation, ratios 0.64--1.94 as unchanged, and ratios \<0.64 as a downregulation of tyrosine phosphorylation. For the CA-CSF-1R/CA-CSF-1R Y561F comparison, fold change ratios \>1.55 were defined as an upregulation in the levels of tyrosine phosphorylation, ratios 0.63--1.55 as unchanged, and ratios \<0.63 as a downregulation of tyrosine phosphorylation. All of the detected phosphopeptides were classified for CSF-1R and SRC regulation on the basis of the calculated relative fold differences ([Table S3](#pone.0013587.s003){ref-type="supplementary-material"}).

Immunoprecipitation and Western blot analysis {#s4e}
---------------------------------------------

Cells were lysed in RIPA lysis buffer supplemented with protease inhibitors and phosphatase inhibitors. Lysates were run on an SDS 10% polyacrylamide gel and transferred onto PVDF membranes (Millipore, Bedford, MA), and immunoblots were visualized with an enhanced chemiluminescence kit (Perkin Elmer, Boston, MA).

Phosphorylation Motif Analysis Using Motif-X {#s4f}
--------------------------------------------

The Motif-X algorithm [@pone.0013587-Schwartz1] was used to extract significantly enriched phosphorylation motifs from the phosphopeptide data set. The identified peptides were centered at the phosphorylated amino acid and aligned by the algorithm using the human MS proteome. The probability threshold was set to P\<10^−4^, and the occurrence threshold was set to a minimum of four peptides.

Biological process enrichment analysis {#s4g}
--------------------------------------

Proteins identified from the PhosphoScan® analysis were assessed for enrichment of Gene Ontology and GeneGO® categories using GeneGO® software (<http://www.genego.com>). The enrichment analysis computes the probability that a set of genes that are annotated within a specific category would occur by chance and the results are given in the form of p-values. The enrichment score provided on bar graphs is computed as −log(p-value).

Comparative Bioinformatics Analysis {#s4h}
-----------------------------------

Phosphorylated proteins from the CSF-1R/SRC PhosphoScan® analysis were compared to published mass spectrometry datasets using BioConductor/R (<http://www.bioconductor.org/>). SwissProt identifiers from the CSF-1R study were mapped to human and mouse Entrez Gene Identifiers and merged to Entrez Gene Identifiers mapped identifiers provided in published studies. Networks showing the degree of overlap were generated in Cytoscape using the Cerebral Plug-in. Overlap with published tumor data sets was performed with a custom Perl script that identifies overlapping peptides on the basis of peptide sequence. Correlation p-values were calculated using the right-sided Fisher\'s exact test. To determine whether the phosphorylated proteins from the CSF-1R/SRC PhosphoScan® analysis have been previously linked to CSF-1R signaling, a comprehensive CSF-1R protein interaction network was generated using the Grow Tool in Ingenuity Pathways Analysis (Ingenuity® Systems, [www.ingenuity.com](http://www.ingenuity.com)). The genes from this network were cross-referenced to the proteins from the PhosphoScan® analysis.
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